Clinical trials: High Risk Medications
Hypertension
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
- Trial name
- NCT00696384
- Testing
- Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
- Where
- 45 sites in United States, Argentina and 1 more
- Volunteers
- 418 people
- Sponsor
- Takeda
Uterine Fibroids, Osteoporosis
Women's Use of Alternative Medicine: A Multiethnic Study
The purpose of this study is to examine socio-cultural factors of women's use of complementary and alternative medicine (CAM). The effects of socioeconomic status, social networks and acculturation on CAM use will be assessed…
- Conditions
- Uterine Fibroids, Osteoporosis, Urinary Tract Infection, High Blood Pressure
- Trial name
- NCT00067249
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Infant Newborn Disease
Multidrug Resistant Gram-negative Pathogen Infections in High Risk Neonates in the Northeast of Mexico
The main objective of this project is to establish a prospective cohort to measure the Gram-negative infection burden in neonates under special care in a regional referral hospital, and to characterize all microorganisms isolates…
- Trial name
- InfGNMDR-Neo (NCT04812847)
- Testing
- Identification of MDR characteristics
- Where
- Mexico
- Volunteers
- 597 people
- Sponsor
- Instituto Tecnologico y de Estudios Superiores de Monterey
Acute Mountain Sickness
Drug Combination on Exercise Performance at High Altitude
This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at…
- Trial name
- NCT01902758
- Testing
- ambrisentan and theophylline
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Montana
Adverse Drug Event
Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention
Reducing medications and associated side effects in older adults: an electronic hospital-based intervention
- Trial name
- NCT03272607
- Testing
- Deprescribing opportunities
- Where
- 7 sites in Canada
- Volunteers
- 6,582 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
Substance-related Disorders, Depression
Primary Care iSBIRT to Reduce Serious Teen Health Risks
The goal of the project is to develop and test an internet/intranet-based Screening, Brief Intervention, and Referral to Treatment (iSBIRT) system for adolescents that targets a broad range of serious health-risks and problem…
- Conditions
- Substance-related Disorders, Depression, High-risk Sex
- Trial name
- NCT00891631
- Testing
- iSBIRT, iSBIRT/TE
- Where
- United States
- Sponsor
- Boston Children's Hospital
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
This phase II trial compares the effect of usual radiation therapy with cisplatin/carboplatin (chemoradiation) to the addition of xevinapant with chemoradiation in patients with head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06084845
- Testing
- Biospecimen Collection, Carboplatin, Chest Radiography
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Drug Safety
Data-driven Quality Improvement in Primary Care - Trial
A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.
- Trial name
- DQIP (NCT01425502)
- Testing
- DQIP Intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
This study assesses the effectiveness of reactive focal mass drug administration (rfMDA), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district)…
- Trial name
- COMBAT (NCT05052502)
- Testing
- Case Management and Follow-up, Reactive focal mass drug administration (rfMDA)
- Where
- Thailand
- Volunteers
- 14,977 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Substance Use, Harm Reduction
A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students
The primary goal of this study is to test the effectiveness of the iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) curriculum, a novel drug education and diversion program, in approximately 300…
- Conditions
- Substance Use, Harm Reduction, Adolescent Behavior
- Trial name
- NCT06115746
- Testing
- iDECIDE
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Massachusetts General Hospital
Neoplasms, Ovarian
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS…
- Trial name
- NCT05613088
- Testing
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 50 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Recurrence
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
Atrial Fibrillation (AF) is the most common abnormal heart rhythm(arrhythmia) affecting about one in 40 people in England. Patients with AF often have symptoms ranging from palpitations and breathlessness, and a small number of…
- Conditions
- Atrial Fibrillation, Recurrence, Overweight and Obesity, Liraglutide
- Trial name
- GOAL-AF (NCT05221229)
- Testing
- Liraglutide plus upstream risk factors modification advice and consultation
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University Hospital Birmingham
Cytomegalovirus Retinitis, HIV Infections
Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
To study the use of acyclovir (ACV) and zidovudine (AZT) in the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS who would otherwise be treated with ganciclovir (DHPG) alone.
- Trial name
- NCT00000693
- Testing
- Zidovudine, Acyclovir
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sarcoma, Sarcoma, Leiomyo-, Adult
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma…
- Conditions
- Sarcoma, Sarcoma, Leiomyo-, Adult, Sarcoma, Synovial, Adult, Soft Tissue Sarcoma (STS)
- Trial name
- PANTHR-S (NCT07432932)
- Testing
- Observational Translational Study
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Burkitt Lymphoma, Double-Expressor Lymphoma
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma.
- Conditions
- Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- Trial name
- NCT07069699
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Hypertension
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696436
- Testing
- Azilsartan medoxomil, Valsartan, Olmesartan
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,291 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept
The purpose of this study is to determine whether the blood levels of abatacept drug product manufactured using High Metals and using Low Metals are comparable in healthy subjects.
- Trial name
- NCT01221636
- Testing
- Abatacept
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb